Investor Relations Captor Therapeutics ®
Allocation of series P ordinary bearer shares of the Company
Current report no. 44/2023
Date: 29 September 2023
Subject: Allocation of series P ordinary bearer shares of the Company
Legal basis: Article 17(1) MAR - confidential information.
The Management Board of Captor Therapuetics S.A., based in Wrocław, Poland (the "Company"), with reference to: current report no. 41/2023 of 21 September 2023, current report no. 42/2023 of 21 September 2023 and current report no. 43/2023 of 22 September 2023, announces that on 29 September 2023, the management board of the Company adopted a resolution on the allocation of 400,000 series P ordinary bearer shares of the Company with a nominal value of PLN 0.10 each and a total nominal value of PLN 40,000.00 ("Series P Shares"). At the same time, the Company announces that to date, share subscription agreements have been concluded with investors subscribing for Series P Shares and the required cash contributions have been made in full by all subscribers of Series P Shares.
This current report has been prepared solely for the purpose of fulfilling the obligations arising from Article 17(1) of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse Regulation and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC MAR, as the Company has determined that the above information meets the criteria of confidential information within the meaning of Article 7 MAR. This report is in no way intended to promote, directly or indirectly, the offer, subscription or purchase of the P Shares and does not constitute advertising or promotional material prepared or published by the Company for the purpose of promoting the P Share Offer or to encourage investors, directly or indirectly, to purchase or subscribe for the SeriesP Shares.